Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study.
Journal
Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R
Informations de publication
Date de publication:
12 Oct 2019
12 Oct 2019
Historique:
received:
23
07
2019
revised:
30
07
2019
accepted:
01
08
2019
pubmed:
7
9
2019
medline:
24
10
2019
entrez:
7
9
2019
Statut:
ppublish
Résumé
A small proportion of patients undergoing primary prophylactic implantation of implantable cardioverter defibrillators (ICDs) experiences malignant arrhythmias. We postulated that periodic repolarisation dynamics, a novel marker of sympathetic-activity-associated repolarisation instability, could be used to identify electrically vulnerable patients who would benefit from prophylactic implantation of ICDs by way of a reduction in mortality. We did a prespecified substudy of EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD), a prospective, investigator-initiated, non-randomised, controlled cohort study done at 44 centres in 15 EU countries. Patients aged 18 years or older with ischaemic or non-ischaemic cardiomyopathy and reduced left ventricular ejection fraction (≤35%) were eligible for inclusion if they met guideline-based criteria for primary prophylactic implantation of ICDs. Periodic repolarisation dynamics from 24-h Holter recordings were assessed blindly in patients the day before ICD implantation or on the day of study enrolment in patients who were conservatively managed. The primary endpoint was all-cause mortality. Propensity scoring and multivariable models were used to assess the interaction between periodic repolarisation dynamics and the treatment effect of ICDs on mortality. Between May 12, 2014, and Sept 7, 2018, 1371 patients were enrolled in our study. 968 of these patients underwent ICD implantation, and 403 were treated conservatively. During follow-up (median 2·7 years [IQR 2·0-3·3] in the ICD group and 1·2 years [0·8-2·7] in the control group), 138 (14%) patients died in the ICD group and 64 (16%) patients died in the control group. We noted a 43% reduction in mortality in the ICD group compared with the control group (adjusted hazard ratio [HR] 0·57 [95% CI 0·41-0·79]; p=0·0008). Periodic repolarisation dynamics significantly predicted the treatment effect of ICDs on mortality (adjusted p=0·0307). The mortality benefits associated with ICD implantation were greater in patients with periodic repolarisation dynamics of 7·5 deg or higher (n=199; adjusted HR 0·25 [95% CI 0·13-0·47] for the ICD group vs the control group; p<0·0001) than in those with periodic repolarisation dynamics less than 7·5 deg (n=1166; adjusted HR 0·69 [95% CI 0·47-1·00]; p=0·0492; p Periodic repolarisation dynamics predict mortality reductions associated with prophylactic implantation of ICDs in contemporarily treated patients with ischaemic or non-ischaemic cardiomyopathy. Periodic repolarisation dynamics could help to guide treatment decisions about prophylactic ICD implantation. The European Community's 7th Framework Programme.
Sections du résumé
BACKGROUND
BACKGROUND
A small proportion of patients undergoing primary prophylactic implantation of implantable cardioverter defibrillators (ICDs) experiences malignant arrhythmias. We postulated that periodic repolarisation dynamics, a novel marker of sympathetic-activity-associated repolarisation instability, could be used to identify electrically vulnerable patients who would benefit from prophylactic implantation of ICDs by way of a reduction in mortality.
METHODS
METHODS
We did a prespecified substudy of EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD), a prospective, investigator-initiated, non-randomised, controlled cohort study done at 44 centres in 15 EU countries. Patients aged 18 years or older with ischaemic or non-ischaemic cardiomyopathy and reduced left ventricular ejection fraction (≤35%) were eligible for inclusion if they met guideline-based criteria for primary prophylactic implantation of ICDs. Periodic repolarisation dynamics from 24-h Holter recordings were assessed blindly in patients the day before ICD implantation or on the day of study enrolment in patients who were conservatively managed. The primary endpoint was all-cause mortality. Propensity scoring and multivariable models were used to assess the interaction between periodic repolarisation dynamics and the treatment effect of ICDs on mortality.
FINDINGS
RESULTS
Between May 12, 2014, and Sept 7, 2018, 1371 patients were enrolled in our study. 968 of these patients underwent ICD implantation, and 403 were treated conservatively. During follow-up (median 2·7 years [IQR 2·0-3·3] in the ICD group and 1·2 years [0·8-2·7] in the control group), 138 (14%) patients died in the ICD group and 64 (16%) patients died in the control group. We noted a 43% reduction in mortality in the ICD group compared with the control group (adjusted hazard ratio [HR] 0·57 [95% CI 0·41-0·79]; p=0·0008). Periodic repolarisation dynamics significantly predicted the treatment effect of ICDs on mortality (adjusted p=0·0307). The mortality benefits associated with ICD implantation were greater in patients with periodic repolarisation dynamics of 7·5 deg or higher (n=199; adjusted HR 0·25 [95% CI 0·13-0·47] for the ICD group vs the control group; p<0·0001) than in those with periodic repolarisation dynamics less than 7·5 deg (n=1166; adjusted HR 0·69 [95% CI 0·47-1·00]; p=0·0492; p
INTERPRETATION
CONCLUSIONS
Periodic repolarisation dynamics predict mortality reductions associated with prophylactic implantation of ICDs in contemporarily treated patients with ischaemic or non-ischaemic cardiomyopathy. Periodic repolarisation dynamics could help to guide treatment decisions about prophylactic ICD implantation.
FUNDING
BACKGROUND
The European Community's 7th Framework Programme.
Identifiants
pubmed: 31488371
pii: S0140-6736(19)31996-8
doi: 10.1016/S0140-6736(19)31996-8
pii:
doi:
Types de publication
Controlled Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1344-1351Investigateurs
Béla Merkely
(B)
Peter Perge
(P)
Zoltan Sallo
(Z)
Gabor Szeplaki
(G)
Markus Zabel
(M)
Lars Lüthje
(L)
Simon Schlögl
(S)
Helge Haarmann
(H)
Leonard Bergau
(L)
Joachim Seegers
(J)
Gerd Hasenfuß
(G)
Pascal Munoz-Exposito
(P)
Tobias Tichelbäcker
(T)
Aleksandra Kirova
(A)
Tim Friede
(T)
Markus Harden
(M)
Marek Malik
(M)
Katerina Hnatkova
(K)
Marc Vos
(M)
Stefan N Willich
(SN)
Thomas Reinhold
(T)
Rik Willems
(R)
Bert Vandenberk
(B)
Magdalena Klinika
(M)
Krapinske Toplice
(K)
Panayota Flevari
(P)
Andreas Katsimardos
(A)
Dimitrios Katsaras
(D)
Robert Hatala
(R)
Martin Svetlosak
(M)
Andrzej Lubinski
(A)
Tomasz Kuczejko
(T)
Jim Hansen
(J)
Christian Sticherling
(C)
David Conen
(D)
Sestre Milosrdnice
(S)
Nikola Pavlović
(N)
Šime Manola
(Š)
Ozren Vinter
(O)
Ivica Benko
(I)
Anton Tuinenburg
(A)
Axel Bauer
(A)
Christine Meyer-Zürn
(C)
Christian Eick
(C)
Jesper Hastrup
(J)
Josep Brugada
(J)
Elena Arbelo
(E)
Gabriela Kaliska
(G)
Jozef Martinek
(J)
Michael Dommasch
(M)
Alexander Steger
(A)
Stefan Kääb
(S)
Moritz F Sinner
(MF)
Konstantinos D Rizas
(KD)
Wolfgang Hamm
(W)
Nikolay Vdovin
(N)
Mathias Klemm
(M)
Lukas von Stülpnagel
(L)
Iwona Cygankiewicz
(I)
Pawel Ptaszynski
(P)
Krzysztof Kaczmarek
(K)
Izabela Poddebska
(I)
Svetoslav Iovev
(S)
Tomáš Novotný
(T)
Milan Kozak
(M)
Heikki Huikuri
(H)
Tuomas Kenttä
(T)
Ari Pelli
(A)
Jaroslaw D Kasprzak
(JD)
Dariusz Qavoq
(D)
Sandro Brusich
(S)
Ervin Avdovic
(E)
Marina Klasan
(M)
Jan Galuszka
(J)
Milos Taborsky
(M)
Vasil Velchev
(V)
Rüdiger Dissmann
(R)
Przemysław Guzik
(P)
Dieter Bimmel
(D)
Christiane Lieberz
(C)
Stefan Stefanow
(S)
Norman Rüb
(N)
Christian Wolpert
(C)
Lars S Maier
(LS)
Steffen Behrens
(S)
Zrinka Jurisic
(Z)
Frieder Braunschweig
(F)
Florian Blaschke
(F)
Burkert Pieske
(B)
Zoran Bakotic
(Z)
Ante Anic
(A)
Robert H G Schwinger
(RHG)
Pyotr Platonov
(P)
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.